7F2X

Crystal structure of MEK1 C121S mutant

7F2X の概要

• エントリーDOI: 10.2210/pdb7f2x/pdb
• 分子名称: MEK1 F11, PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER (3 entities in total)
• 機能のキーワード: kinase, signaling protein
• 由来する生物種: Homo sapiens
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 36219.26

構造登録者

Fujioka, Y.,Noda, N.N. (登録日: 2021-06-15, 公開日: 2022-06-22, 最終更新日: 2023-11-29)

主引用文献

Kubota, Y.,Fujioka, Y.,Patil, A.,Takagi, Y.,Matsubara, D.,Iijima, M.,Momose, I.,Naka, R.,Nakai, K.,Noda, N.N.,Takekawa, M.
Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.
Nat Commun, 13:4063-4063, 2022

PubMed Abstract: Point-mutations of MEK1, a central component of ERK signaling, are present in cancer and RASopathies, but their precise biological effects remain obscure. Here, we report a mutant MEK1 structure that uncovers the mechanisms underlying abnormal activities of cancer- and RASopathy-associated MEK1 mutants. These two classes of MEK1 mutations differentially impact on spatiotemporal dynamics of ERK signaling, cellular transcriptional programs, gene expression profiles, and consequent biological outcomes. By making use of such distinct characteristics of the MEK1 mutants, we identified cancer- and RASopathy-signature genes that may serve as diagnostic markers or therapeutic targets for these diseases. In particular, two AKT-inhibitor molecules, PHLDA1 and 2, are simultaneously upregulated by oncogenic ERK signaling, and mediate cancer-specific ERK-AKT crosstalk. The combined expression of PHLDA1/2 is critical to confer resistance to ERK pathway-targeted therapeutics on cancer cells. Finally, we propose a therapeutic strategy to overcome this drug resistance. Our data provide vital insights into the etiology, diagnosis, and therapeutic strategy of cancers and RASopathies.

PubMed: 35831322
DOI: 10.1038/s41467-022-31690-w

実験手法

X-RAY DIFFRACTION (2.007 Å)